norethindrone acetate has been researched along with Atypical Endometrial Hyperplasia in 24 studies
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.
Atypical Endometrial Hyperplasia: A benign form of endometrial hyperplasia with increased number of cells with atypia. The atypical cells are large and irregular and have an increased nuclear/cytoplasmic ratio. The risk of progression to endometrial carcinoma rises with the increasing degree of cell atypia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effectiveness of dienogest (DIE) and norethisterone acetate (NETA) regimens in the treatment of endometrial hyperplasia (EH) without atypia." | 9.69 | Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia. ( Abdeldayem, HM; Girbash, EF; Radwan, AM; Sherif, HE, 2023) |
| "A group of 56 premenopausal women with non-atypical endometrial hyperplasia were enrolled and received: genistein aglycone (n=19; 54 mg/day); norethisterone acetate (n=19; 10 mg/day on days 16-25 of the menstrual cycle) or placebo (n=18) for 6 months." | 9.14 | Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. ( Adamo, EB; Altavilla, D; Bitto, A; D'Anna, R; Giordano, D; Granese, R; Maisano, D; Marini, H; Nicotina, PA; Squadrito, F; Triolo, O; Villari, D, 2010) |
| "To determine whether a continuous estradiol-norethindrone acetate transdermal delivery system reduces incidence of endometrial hyperplasia in postmenopausal women more than transdermal estradiol (E2) alone." | 9.09 | A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. ( Archer, DF; Dain, MP; Furst, K; Tipping, D; Vandepol, C, 1999) |
| "To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of endometrial hyperplasia associated with unopposed 17beta-estradiol (E2), 1 mg." | 9.09 | Norethindrone acetate and estradiol-induced endometrial hyperplasia. ( Arce, J; Archer, DF; Félix, JC; Kurman, RJ; Moyer, DL; Nanavati, N, 2000) |
| "To compare the effectiveness of dienogest (DIE) and norethisterone acetate (NETA) regimens in the treatment of endometrial hyperplasia (EH) without atypia." | 5.69 | Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia. ( Abdeldayem, HM; Girbash, EF; Radwan, AM; Sherif, HE, 2023) |
| "The objective of this study was to assess effectiveness and safety of Depo-Provera (medroxyprogesterone acetate) in treatment of endometrial hyperplasia (EH) and to compare it with norethisterone acetate (NETA) as an oral progestogen treatment." | 5.22 | Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia. ( Abdel-Raouf, SM; Abdeldayem, HM; Arafa, EM; Atwa, K; Girbash, EF; Nooh, AM, 2016) |
| "A group of 56 premenopausal women with non-atypical endometrial hyperplasia were enrolled and received: genistein aglycone (n=19; 54 mg/day); norethisterone acetate (n=19; 10 mg/day on days 16-25 of the menstrual cycle) or placebo (n=18) for 6 months." | 5.14 | Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. ( Adamo, EB; Altavilla, D; Bitto, A; D'Anna, R; Giordano, D; Granese, R; Maisano, D; Marini, H; Nicotina, PA; Squadrito, F; Triolo, O; Villari, D, 2010) |
| "The purpose of this study was to determine the incidence of endometrial hyperplasia in subjects who receive continuous norethindrone acetate and ethinyl estradiol combinations versus unopposed ethinyl estradiol." | 5.10 | A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone. ( Kempfert, NJ; Portman, DJ; Symons, JP; Wilborn, W, 2003) |
| "To determine whether a continuous estradiol-norethindrone acetate transdermal delivery system reduces incidence of endometrial hyperplasia in postmenopausal women more than transdermal estradiol (E2) alone." | 5.09 | A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. ( Archer, DF; Dain, MP; Furst, K; Tipping, D; Vandepol, C, 1999) |
| "To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of endometrial hyperplasia associated with unopposed 17beta-estradiol (E2), 1 mg." | 5.09 | Norethindrone acetate and estradiol-induced endometrial hyperplasia. ( Arce, J; Archer, DF; Félix, JC; Kurman, RJ; Moyer, DL; Nanavati, N, 2000) |
| "To assess prospectively the effect on bleeding patterns, transformation of the endometrium, and rate of endometrial hyperplasia of transdermal norethisterone acetate when administered sequentially in combination with transdermal estradiol (E2), and to compare it to a regimen using oral medroxyprogesterone acetate." | 5.07 | Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. ( Boyd, ME; Colgan, TJ; Ferenczy, A; Fugere, P; Lorrain, J; Ross, AH, 1993) |
| "For the first 3 months, vaginal bleeding/spotting rate for the CEE/MPA group was 38." | 2.72 | Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. ( Eren, S; Pekin, O; Tugrul, S; Uslu, H; Yildirim, G, 2006) |
| " Both treatments were generally well tolerated, with most adverse events (>90%) being mild to moderate, although minor differences in the tolerability profile were observed between treatments." | 2.72 | Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. ( Arguinzoniz, M; Boschitsch, E; Concin, H; De Geyter, C; Ehrenborg, A; Heikkinen, J; Hobson, R; Ibarra de Palacios, P; Samsioe, G; Scheurer, C; Schmidt, G, 2006) |
| "Endometrial hyperplasia was not observed in the group receiving NA/EE 0." | 2.43 | Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. ( Ellman, H; Rowan, JP; Simon, JA; Speroff, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 3 (12.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Girbash, EF | 2 |
| Sherif, HE | 1 |
| Radwan, AM | 1 |
| Abdeldayem, HM | 2 |
| Caserta, D | 1 |
| Matteucci, E | 1 |
| Ralli, E | 1 |
| Mallozzi, M | 1 |
| Bordi, G | 1 |
| Moscarini, M | 1 |
| Nooh, AM | 1 |
| Arafa, EM | 1 |
| Atwa, K | 1 |
| Abdel-Raouf, SM | 1 |
| Bitto, A | 1 |
| Granese, R | 1 |
| Triolo, O | 1 |
| Villari, D | 1 |
| Maisano, D | 1 |
| Giordano, D | 1 |
| Altavilla, D | 1 |
| Marini, H | 1 |
| Adamo, EB | 1 |
| Nicotina, PA | 1 |
| D'Anna, R | 1 |
| Squadrito, F | 1 |
| Wells, M | 2 |
| Sturdee, DW | 2 |
| Barlow, DH | 2 |
| Ulrich, LG | 2 |
| O'Brien, K | 1 |
| Campbell, MJ | 2 |
| Vessey, MP | 2 |
| Bragg, AJ | 2 |
| Portman, DJ | 1 |
| Symons, JP | 1 |
| Wilborn, W | 1 |
| Kempfert, NJ | 1 |
| TAYMOR, ML | 1 |
| RIZKALLAH, T | 1 |
| Koninckx, PR | 1 |
| Spielmann, D | 1 |
| Yildirim, G | 1 |
| Tugrul, S | 1 |
| Uslu, H | 1 |
| Pekin, O | 1 |
| Eren, S | 1 |
| Popp, AW | 1 |
| Bodmer, C | 1 |
| Senn, C | 1 |
| Fuchs, G | 1 |
| Kraenzlin, ME | 1 |
| Wyss, H | 1 |
| Birkhaeuser, MH | 1 |
| Lippuner, K | 1 |
| Rowan, JP | 1 |
| Simon, JA | 1 |
| Speroff, L | 1 |
| Ellman, H | 1 |
| Samsioe, G | 1 |
| Boschitsch, E | 1 |
| Concin, H | 1 |
| De Geyter, C | 1 |
| Ehrenborg, A | 1 |
| Heikkinen, J | 1 |
| Hobson, R | 1 |
| Arguinzoniz, M | 1 |
| Ibarra de Palacios, P | 1 |
| Scheurer, C | 1 |
| Schmidt, G | 1 |
| Casey, CL | 1 |
| Murray, CA | 1 |
| Gambrell, RD | 1 |
| Massey, FM | 1 |
| Castaneda, TA | 1 |
| Ugenas, AJ | 1 |
| Ricci, CA | 1 |
| Wright, JM | 1 |
| Ross, AH | 1 |
| Boyd, ME | 1 |
| Colgan, TJ | 1 |
| Ferenczy, A | 1 |
| Fugere, P | 1 |
| Lorrain, J | 1 |
| Saure, A | 1 |
| Hirvonen, E | 1 |
| Milsom, I | 1 |
| Christensen, A | 1 |
| Damber, MG | 1 |
| Pérez-Medina, T | 1 |
| Bajo, J | 1 |
| Folgueira, G | 1 |
| Haya, J | 1 |
| Ortega, P | 1 |
| Archer, DF | 2 |
| Furst, K | 1 |
| Tipping, D | 1 |
| Dain, MP | 1 |
| Vandepol, C | 1 |
| Bjarnason, K | 1 |
| Cerin, A | 1 |
| Lindgren, R | 2 |
| Weber, T | 1 |
| Kurman, RJ | 1 |
| Félix, JC | 1 |
| Nanavati, N | 1 |
| Arce, J | 1 |
| Moyer, DL | 1 |
| Nielsen, B | 1 |
| Anderson, MC | 1 |
| Risberg, B | 1 |
| Hammar, M | 1 |
| Berg, G | 1 |
| Pryse-Davies, J | 1 |
| Krafft, W | 1 |
| Griesinger, R | 1 |
| Schindler, AE | 1 |
2 reviews available for norethindrone acetate and Atypical Endometrial Hyperplasia
| Article | Year |
|---|---|
Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
Topics: Bone Density; Endometrial Hyperplasia; Estrogen Replacement Therapy; Ethinyl Estradiol; Female; Hot | 2006 |
HT update: spotlight on estradiol/norethindrone acetate combination therapy.
Topics: Bone Density; Breast Neoplasms; Colorectal Neoplasms; Contraceptives, Oral, Synthetic; Drug Combinat | 2008 |
16 trials available for norethindrone acetate and Atypical Endometrial Hyperplasia
| Article | Year |
|---|---|
Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia.
Topics: Endometrial Hyperplasia; Endometrium; Estradiol; Female; Humans; Male; Nandrolone; Norethindrone; No | 2023 |
Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia.
Topics: Administration, Oral; Adult; Contraceptive Agents, Female; Disease Management; Endometrial Hyperplas | 2016 |
Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia.
Topics: Adult; Contraceptives, Oral, Synthetic; Double-Blind Method; Endometrial Hyperplasia; Endometrium; F | 2010 |
A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone.
Topics: Double-Blind Method; Drug Combinations; Endometrial Hyperplasia; Endometrium; Estradiol Congeners; E | 2003 |
A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women.
Topics: Administration, Oral; Adult; Body Weight; Double-Blind Method; Drug Administration Schedule; Drug Co | 2005 |
Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
Topics: Adult; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Con | 2006 |
Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Topics: Body Mass Index; Bone Density; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Replacement | 2006 |
Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Drug Therapy, Combination; Endometrial | 2006 |
Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Biopsy; Drug Therapy, Combination; Endometri | 1993 |
A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
Topics: Administration, Oral; Climacteric; Desogestrel; Double-Blind Method; Endometrial Hyperplasia; Endome | 1996 |
Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up.
Topics: Adult; Aged; Endometrial Hyperplasia; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Hum | 1999 |
A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.
Topics: Administration, Cutaneous; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Endometrial | 1999 |
Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group.
Topics: Biopsy; Endometrial Hyperplasia; Estradiol; Female; Hormone Replacement Therapy; Humans; Incidence; | 1999 |
Norethindrone acetate and estradiol-induced endometrial hyperplasia.
Topics: Climacteric; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dr | 2000 |
The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.
Topics: Administration, Oral; Adult; Aged; Drug Combinations; Endometrial Hyperplasia; Estradiol; Estradiol | 2000 |
Endometrial effects of transdermal estradiol/norethisterone acetate.
Topics: Administration, Cutaneous; Adult; Aged; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Re | 1992 |
6 other studies available for norethindrone acetate and Atypical Endometrial Hyperplasia
| Article | Year |
|---|---|
A 29-year-old woman with complex atypical hyperplasia and polycystic ovary syndrome: a challenging issue.
Topics: Adult; Endometrial Hyperplasia; Female; Fertility Preservation; Humans; Norethindrone; Norethindrone | 2014 |
Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
Topics: Administration, Oral; Adult; Aged; Contraceptives, Oral, Combined; Endometrial Hyperplasia; Estradio | 2002 |
EFFECT OF NORETHINDRONE ACETATE UPON GONADOTROPIN-INDUCED OVARIAN FUNCTION.
Topics: Amenorrhea; Chorionic Gonadotropin; Drug Therapy; Endometrial Hyperplasia; Estrogens; Female; Follic | 1965 |
Use of the progestogen challenge test to reduce the risk of endometrial cancer.
Topics: Adenocarcinoma; Aged; Endometrial Hyperplasia; Estrogens; Female; Humans; Medroxyprogesterone; Medro | 1980 |
[Therapy of juvenile adenomatous hyperplasia of the endometrium by progesterone stimulation].
Topics: Adenoma; Adolescent; Adult; Chlormadinone Acetate; Drug Administration Schedule; Endometrial Hyperpl | 1989 |
[Therapy with gestagens in hyperplastic changes of the endometrium].
Topics: Adenocarcinoma; Adenoma; Endometrial Hyperplasia; Endometrium; Female; Humans; Medroxyprogesterone; | 1986 |